阿哌沙班与利伐沙班相关脑出血的血肿体积比较
该单中心回顾性队列纳入2013–2024年136例阿哌沙班或利伐沙班相关自发性脑出血患者(阿哌沙班91例,利伐沙班45例)。利伐沙班组基线血肿体积中位数更大(22.8 mL vs 12.2 mL,P=0.003),多因素线性回归显示利伐沙班与更大基线血肿体积独立相关(标准化系数0.581,95%CI 0.146–1.015,P=0.009)。血肿扩大(40.0% vs 23.7%,P=0.131)和院内死亡率(40.0% vs 29.8%,P=0.240)两组相似。结论需更大队列验证。
要点
- 利伐沙班相关脑出血基线血肿体积中位数22.8 mL,大于阿哌沙班的12.2 mL(P=0.003)。
- 多因素线性回归中利伐沙班与更大基线血肿体积独立相关(标准化系数0.581,95%CI 0.146–1.015,P=0.009)。
- 利伐沙班组脑叶出血比例更高(46.7% vs 28.6%,P=0.037)。
- 血肿扩大(>6 cc或>33%)两组无显著差异(40.0% vs 23.7%,P=0.131)。
- 院内死亡率两组无显著差异(40.0% vs 29.8%,P=0.240)。
适用人群与场景
- 2013–2024年单中心连续收治的阿哌沙班或利伐沙班相关自发性脑出血患者,共136例(阿哌沙班91例,利伐沙班45例)。
- 中位年龄81岁(IQR 73–87),女性68例(50.0%)。
诊断标准与关键阈值
- 血肿扩大定义为>6 cc或>33%。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:单中心回顾性队列,样本量136例,无对照干预。
- 利伐沙班组基线血肿体积中位数22.8 mL(IQR 8.0–58.0),阿哌沙班组12.2 mL(IQR 2.5–31.2),P=0.003。
- 多因素线性回归:利伐沙班与更大基线血肿体积独立相关,标准化系数0.581(95%CI 0.146–1.015),P=0.009。
- 脑叶出血比例:利伐沙班46.7%,阿哌沙班28.6%,P=0.037。
- 血肿扩大:利伐沙班40.0%,阿哌沙班23.7%,P=0.131。
- 院内死亡率:利伐沙班40.0%,阿哌沙班29.8%,P=0.240。
证据类型、等级与局限
- 证据类型:单中心回顾性队列研究。
- 局限:回顾性设计、单中心、样本量小(136例),作者指出需更大队列验证。
对床旁实践的改变
- 对于利伐沙班相关自发性脑出血患者,应意识到其基线血肿体积可能大于阿哌沙班相关脑出血,但血肿扩大和院内死亡率无显著差异。
- 该研究为回顾性单中心证据,不能据此改变抗凝药物选择或急性期血肿清除决策。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND/OBJECTIVE: Among patients with intracerebral hemorrhage (ICH) associated with direct oral anticoagulant (DOAC) use, it is unknown whether hematoma volume differs according to DOAC agent. The primary objective of our study was to compare baseline hematoma volume between apixaban and rivaroxaban-related ICH.
METHODS: We evaluated consecutive patients with apixaban- and rivaroxaban-related spontaneous ICH admitted to a tertiary hospital between 2013 and 2024. We recorded baseline hematoma volume, hematoma expansion (> 6 cc or > 33%), and hospital mortality.
RESULTS: The cohort comprised 136 patients (age, median [IQR] 81 [73-87] years, 68 female [50.0%]); of whom 91 (66.9%) were taking apixaban and 45 (33.1%) were taking rivaroxaban at the time of the index ICH. There were no differences in demographics, comorbidities, or antiplatelet pretreatment between apixaban and rivaroxaban. Lobar hemorrhage location was more frequent with rivaroxaban (46.7% vs. 28.6%, P = 0.037). Rivaroxaban-related ICH patients had larger median baseline hematoma volumes (22.8 [8.0-58.0] mL vs. 12.2 [2.5-31.2] mL; P = 0.003) compared with apixaban. In multivariable linear regression analysis, rivaroxaban was independently associated with larger baseline hematoma volume (standardized linear regression coefficient: 0.581 [95% CI 0.146-1.015]; P = 0.009). Hematoma expansion (40.0% vs. 23.7%; P = 0.131) and hospital mortality (40.0% vs. 29.8%; P = 0.240) were similar between rivaroxaban and apixaban.
CONCLUSIONS: Compared with apixaban, rivaroxaban pretreatment was independently associated with larger baseline hematoma volume in patients with spontaneous ICH. These findings require validation in larger cohort studies.
参考来源
- Wilson M, Vu S, Heistand E, et al. Hematoma Volume in Apixaban vs. Rivaroxaban-Related Intracerebral Hemorrhage. Neurocrit Care. 2026. PMID: 42498894. doi:10.1007/s12028-026-02587-z
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。